[Treatment of reflex vagal hypertonia in infants. Role of diphemanil (apropos of 50 cases)].
For a period of 20 months, 50 consecutive infants (mean age: 11 months) were given Diphemanil (atropine like synthetic drug) for reflex symptomatic bradycardia of probable vagal origin. Treatment's results were evaluated with the study of oculo-cardiac reflex (OCR) and Holter monitoring performed before and 3 months after the beginning of Diphemanil. If tolerance was generally good, it was not possible to demonstrate the clinical efficacy of the treatment on the whole group. However, assertive success was seen on individual cases. Holter and OCR data improved statistically. The other therapeutical means aiming at warning possible complications of the hypertonic vagal reflex were reviewed: inserting a cardiac pace-maker does not always prevent sudden death; a nodal sinus surgical selective denervation might be justified in certain exceptional cases, because of the severity of the spontaneous evolution or of the resistance to medical treatment.
D001919:Bradycardia / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D002675:Child, Preschool; D003389:Cranial Nerve Diseases / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D013398:Sudden Infant Death / Q000517:prevention & control; D014630:Vagus Nerve / Q000503:physiopathology*
D010276:Parasympatholytics; D010880:Piperidines; C028209:diphemanil methylsulfate
Traitement de l'hypertonie vagale réflexe du nourrisson. Place du diphémanil (à propos de 50 cas).